Nonclinical development of RNA cancer vaccines: proof-of-concept testing, safety study design, and future prospects
Vaccine Insights 2023; 2(10), 417–427
RNA-based vaccines are nascent technology currently in development for the treatment of multiple types of cancer. Prior to administration in a clinical trial, nonclinical testing of RNA-based vaccines is required to evaluate activity and characterize safety. This article will discuss:
- Example types of mRNA cancer vaccines;
- Commonly used delivery methods for RNAs;
- Nonclinical approaches for evaluating activity;
- Considerations for evaluating safety; and
- Future prospects for RNA cancer therapeutics.